Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Covigenix VAX-001 placebo
- Development stage
- Unknown
- Lead developer
- Entos Pharmaceuticals
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Covigenix VAX-001 placebo is the inactive control substance used in clinical trials for Covigenix VAX-001, a plasmid DNA vaccine developed by Entos Pharmaceuticals for the prevention of COVID-19. The active vaccine candidate utilizes the proprietary Fusogenix proteolipid vehicle (PLV) platform to deliver a DNA plasmid encoding the SARS-CoV-2 Spike protein. The placebo is administered via intramuscular injection to participants in the control group to provide a baseline for evaluating the safety, tolerability, and immunogenicity of the active vaccine candidate.
- Other names
- Placebo vaccine
Beyond the preview
Go deeper on Covigenix VAX-001 placebo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Covigenix VAX-001 placebo.